

## Drug and Therapeutics Committee – Minutes – Confirmed

<b>Date / Time</b>	Thursday 9 <sup>th</sup> January 2020 8:15am – 9:30am
<b>Venue</b>	Meeting Room 1, ERMEC, HRI
<b>Chair</b>	Prof A Morice, Chair, Professor of Respiratory Medicine
<b>Notes / Action Points</b>	Mrs W Hornsby, Senior Pharmacy Technician
<b>Quorate: Yes / No</b>	Yes

<b>Attendance</b>	Ms J Morgan, Professional Secretary, Senior Principal Pharmacist - Formulary Dr O Ogunbambi, Consultant Rheumatologist Dr A Samson, Infectious Diseases Consultant Mr P O'Brien, Deputy Chief Pharmacist Dr S Raise, GP ER CCG (via phone link) Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Mr S P Gaines, Deputy Chief Pharmacist, Lead Pharmacist Medicine Safety Dr H Klonin, Consultant Paediatrician Prof M Lind, Vice Chair, Professor of Oncology
-------------------	--

<b>Apologies</b>	Mr R Kapur, Vascular Surgeon Mr K McCorry, Medicines Optimisation Pharmacist, NECS
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2020.01.01	<b>Apologies</b>	As above					01.20
2020.01.02	<b>Declarations of Interest</b>	None					01.20
	<b>Lidocaine, Adrenaline Tetracaine (LAT) Gel</b>	Dr Herieven attended D&T as a guest to discuss her application for LAT gel which was deferred in November. Dr Herieven circulated a paper she had written to support the application. Dr Herieven explained to the group that there were a cohort of patients admitted to the paediatric emergency dept who would currently require sedation to enable suturing of a wound which requires use of resus room and multiple staff members. LAT gel is poured directly into the wound to enable suturing without the need for general anaesthetic.	Approved	WH to add to formulary	WH	02.20	
2020.01.03	<b>Minutes of the previous meeting</b>	Accepted as a true record					01.20
2020.01.04	<b>Action Tracker</b>	<p><b>New Product Requests</b> ML had written to Dr Herieven to invite to D&amp;T</p> <p><b>New Product Requests</b> ML has written to applicants and WH has updated formulary</p> <p><b>NICE Guidance</b> JM has requested Dr Harley submit application for Sativex which is on agenda for discussion</p> <p><b>NICE Guidance</b> JM has requested Dr Salawu submit an application for Xeomin for sialhorrea in line with TA605 which is on agenda for discussion</p> <p><b>MHRA DSU</b> JM has informed dermatology of the increased risk of skin cancer related to Ingenol Mebutate</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>		<p>ML</p> <p>ML</p> <p>JM</p> <p>JM</p> <p>JM</p>		

		<p><b>MHRA DSU</b> JM has discussed with pathology the need for CrCl to be included on Lorenzo. eGfr is already included on Lorenzo as part of pathology standards but CrCl is required for calculating doses of certain medicines. ML informed the committee ARIA already had a built in calculation for CrCl based on Cockcroft Gault using patients height and weight.</p> <p><b>SDA Ranitidine</b> POB had circulated the SDA for Ranitidine. POB informed the committee that all oral tablets and liquid had now been recalled and were no longer in the supply chain. The trust had been switching patients to antacids or PPIs. Ranitidine injection has not been recalled and there are currently no supply problems. However the trust has limited the supply of the injection to oncology and other areas are now using injectable PPIs. Famotidine and nizatidine have been added to the formulary but due to unprecedented demand these were no longer available in the supply chain.</p> <p><b>Formulary Review</b> JM and WH have reviewed and updated the vaccine section of the formulary.</p> <p><b>AOB</b> JM to discuss with ML letter to interventional radiology regarding eptifibatide</p> <p><b>AOB</b> WH has removed Eluxadoline from formulary</p>	Action complete		JM		
			Action complete		POB		
			Action complete		JM/WH		
			JM to discuss with ML		JM		
			Action complete		WH		
2020.01.05	<b>New Product Requests</b>	THC:CBD Spray Sativex – Spasticity – Dr J Harley Currently patients receiving treatment with Sativex are private patients or receiving treatment via IFR. NICE NG144 now recommends use in spasticity. Initiation pack is free from manufacturer, payment commences once treatment is proven to work in each individual patient.	Approved	AM to write to applicants and WH to update formulary. Will need to be discussed by CCGs, WH to add to HERPC agenda	AM/WH	02.20	

		<p>Midazolam (AMSED) Unlicensed liquid – Sedation 0-16yrs – D Wright – <b>Referred to SMPC</b> Discussed by SMPC on 8.1.2020 and approved</p> <p>Dymista – Rhinitis – Dr Gordins Application previously rejected due to cost implications versus single component inhalers, price has now reduce making Dymista a viable option</p> <p>Adex Gel – Dry and Inflamed Skin – Dr Zaman</p> <p>Avapritinib – Systemic Mastocytosis – Dr S Green Available on a compassionate use scheme (not EAMS) currently undergoing phase 2 trials. No clinical papers submitted with application only posters.</p> <p>Xeomin (Botulinum Neurotoxin type A) – Sialorrhoea – Dr Salawu Applied for use in line with TA605</p>	<p>Approved</p> <p>Approved</p> <p>Approved subject to completion and inclusion on dermatology guideline</p> <p>To be approved on a case by case basis by AM/ML. Application to be resubmitted once product is licensed</p> <p>Approved</p>	<p>To add to HERPC agenda</p>			
2020.01.06	<b>NICE Guidance</b>	<p><b>November</b> TA610 Pentosan polysulfate sodium for treating bladder pain syndrome (Recommended)</p> <p>TA611 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Recommended)</p> <p>TA612 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (Recommended)</p>	<p>Already in use on formulary to be made RED as PAS scheme only available to trust</p> <p>ARIA form has been received</p> <p>Not on formulary ML will discuss with oncology</p>	<p>Noted</p> <p>Add to formulary</p>			<p>01.20</p> <p>01.20</p>

		TA613 Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (NOT Recommended)	On formulary but not used by HUTH for this indication	No further action			01.20
		CG186 Multiple sclerosis in adults: management	Noted	No further action			01.20
		NG145 Thyroid disease: assessment and management	Noted	No further action			01.20
		NG146 Workplace health: long-term sickness absence and capability to work	Noted	No further action			01.20
		CG164 Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer	Noted	No further action			01.20
		NG143 Fever in under 5s: assessment and initial management Recommends ampicillin which is not on formulary	Noted	No further action			01.20
		NG147 Diverticular disease: diagnosis and management	Noted	No further action			01.20
		<b>December</b>					
		NG23 Menopause: diagnosis and management	Noted	No further action			01.20
		NG148 Acute Kidney Injury, Prevention Detection and Management	Noted	No further action			01.20
		TA 614 Cannabidiol with Clobazam for treating seizures associated with Dravet Syndrome (Recommended)	On formulary	No further action			01.20
		TA 615 Cannabidiol with Clobazam for treating seizures associated with Lennox Gastaut Syndrome (Recommended)	paediatric patients will still be referred to Leeds for treatment				
		TA616 Cladribine for treating relapsing–remitting multiple sclerosis (Recommended)	Noted	No further action			01.20
2020.01.07	<b>MHRA Drug Safety Update</b>	November 19 Yellow fever vaccine – stronger precautions in people with weakened immunity and in those aged 60 years or older	Noted	No further action			01.20
		Carfilzomib – risk of reactivation of Hepatitis B virus The committee discussed the fact that this was true for many chemotherapeutic drugs and that testing is not routinely carried	AS to discuss with Dr Lilley		AS	02.20	

		<p>out. AS agreed to discuss with Dr Lilley</p> <p>December 19 Domperidone for nausea and vomiting lack of efficacy in children; reminder of contraindications in adults and adolescents. HK said that domperidone is still used in paediatrics but not for this indication and informed consent of parents is always obtained</p>	Noted	No further action			01.20
2020.01.08	<b>Change in F&amp;WH Diclofenac to Ibuprofen</b>	<p>POB pointed out that since MHRA alert in Dec 2014 other trust have significantly reduced use of Diclofenac and switched to alternative NSAID HUTHs usage has remained the same and has therefore become an outlier in diclofenac prescribing.</p> <p>At the time of the alert diclofenac was removed from all but Family and Womens stock lists but it was requested that these be checked to ensure no one had reinstated diclofenac use</p>	<p>JM to speak to F&amp;W pharmacist and request issue be raised at Obstetrics governance meeting. JM to check stock lists and remove as appropriate</p>		JM	02.20	
2020.01.09	<b>IV Doxycycline as a Sclerosing Agent</b>	<p>In August 2018 a chairs approval was approved for Mr Tilsed to use unlicensed Doxycycline injection as a sclerosing agent. JM has become aware that recently Mr Platt and Mr Matteucci have also used doxycycline IV as a sclerosing agent in plastics patients without chairs approval</p>	<p>JM to request Mr Platt and Mr Matteucci submit new product request application</p>		JM	02.20	
2020.01.10	<b>Review Terms of Reference</b>	<p>Terms of Reference Review Recommendations made were as follows: Alter membership to show healthgroup responsibility first Add section on Dietetic product approval Remove SG and add JM Executive director membership no longer relevant remove section.</p>	<p>Bring back next month with amendments</p>		JM	02.20	
2020.01.11	<b>Minutes from SMPC</b>	<p>September 2019 DC informed the committee that two meetings had taken place since this one. E prescribing had recently be discussed and DC asked the committee if they would like a pharmacy representative to attend D&amp;T to give an update on eprescribing, the committee felt that this would be a useful exercise</p>	<p>JM to invite Rob Calladine to attend D&amp;T</p>		JM	02.20	
2020.01.12	<b>Minutes from HERPC</b>	<p>Minutes from September 2019</p>	Noted	No further action			01.20
2020.01.13	<b>Regional Medicines</b>	<p>RMOC Position Statement: Oral vitamin B supplementation To be discussed at Medicines Management interface group for</p>	<p>WH to add to MMIG agenda</p>		WH	02.20	

	<b>Optimisation Committees</b>	discussions around writing of new guidelines					
2020.01.14	<b>Correspondence received</b>	NHSE IFR Document highlighting that all IFR will be subject to review to check if still appropriate eg has NICE guidance been published since IFR approval	Noted	No further action			01.20
2020.01.15	<b>Chairs approvals</b>	Sodium Thiosulphate (as NITHIODOTE kit) – calciphylaxis- Dr Kunle Adesina  Belimumab - severe cutaneous lupus – Dr E Baguely Application still required as NICE TA in place  Avapritinib –Systemic Mastocytosis - Dr S Green  Levosimendan -following cardiovascular surgery – Dr C Rigg This is the second request for chairs approval for this drug	OO to discuss with Dr Baguely the need for an application to be submitted to D&T  JM to request application		OO	02.20	
2020.01.16	<b>Issues to escalate to OQC</b>	None this month					01.20
2020.01.17	<b>Any Other Business</b>	OO requested RMOC draft paper on Shared Care Frameworks be added to D&T agenda for discussion next month	WH to add to agenda		WH	02.20	
	<b>Date and Time of Next Meeting</b>	<b>Date:</b> Thursday 13 <sup>th</sup> February 2020 <b>Time:</b> 8.15-9.30am <b>Venue:</b> Board Room, Alderson House, HRI					